Andreas Argyrides
Stock Analyst at Chardan Capital
(4.38)
# 1,301
Out of 4,683 analysts
375
Total ratings
47.2%
Success rate
10.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Initiated: Buy | $6 | $0.8254 | +626.92% | 14 | Aug 19, 2026 | |
| EYPT EyePoint | Downgraded: Hold | $65 → $5 | $5.47 | -8.59% | 2 | Aug 18, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $10 → $13 | $3.69 | +252.30% | 2 | Jul 6, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $4.32 | +85.19% | 20 | Jun 25, 2026 | |
| SVRA Savara | Maintained: Buy | $11 | $5.37 | +104.84% | 6 | Jun 3, 2026 | |
| UTHR United Therapeutics | Rated: Hold | n/a | $518.27 | - | 19 | May 11, 2026 | |
| LRMR Larimar Therapeutics | Rated: Hold | n/a | $4.06 | - | 8 | May 11, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $12.88 | - | 3 | May 11, 2026 | |
| LQDA Liquidia | Rated: Hold | n/a | $74.33 | - | 17 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $0.1431 | - | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $119.05 | - | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.61 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.34 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.30 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.07 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $98 | $71.03 | +37.97% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $26.00 | +53.85% | 7 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $38.83 | +59.67% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $14.22 | +195.36% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $2.15 | +318.60% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $7 | $2.18 | +221.10% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $18.02 | +105.33% | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $0.8987 | n/a | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.022 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $13.22 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $105 | $23.55 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.1595 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $13.19 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $11.07 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $24.00 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $66.99 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $16.90 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $248.85 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.638 | n/a | 6 | Aug 25, 2022 |
Rani Therapeutics Holdings
Aug 19, 2026
Initiated: Buy
Price Target: $6
Current: $0.8254
Upside: +626.92%
EyePoint
Aug 18, 2026
Downgraded: Hold
Price Target: $65 → $5
Current: $5.47
Upside: -8.59%
Opus Genetics
Jul 6, 2026
Maintained: Buy
Price Target: $10 → $13
Current: $3.69
Upside: +252.30%
Aquestive Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $8
Current: $4.32
Upside: +85.19%
Savara
Jun 3, 2026
Maintained: Buy
Price Target: $11
Current: $5.37
Upside: +104.84%
United Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $518.27
Upside: -
Larimar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $4.06
Upside: -
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $12.88
Upside: -
Liquidia
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $74.33
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $0.1431
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $119.05
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.61
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $16.34
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $6.30
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $4.07
Upside: -
Apr 24, 2026
Maintained: Buy
Price Target: $105 → $98
Current: $71.03
Upside: +37.97%
Mar 3, 2026
Maintained: Buy
Price Target: $40
Current: $26.00
Upside: +53.85%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $38.83
Upside: +59.67%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $14.22
Upside: +195.36%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $2.15
Upside: +318.60%
Nov 11, 2025
Maintained: Buy
Price Target: $3 → $7
Current: $2.18
Upside: +221.10%
Oct 9, 2025
Maintained: Buy
Price Target: $37
Current: $18.02
Upside: +105.33%
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $0.8987
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.022
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $13.22
Upside: n/a
Aug 13, 2024
Maintained: Hold
Price Target: $105
Current: $23.55
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.1595
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $13.19
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $11.07
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $24.00
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $66.99
Upside: n/a
Feb 22, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $16.90
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $248.85
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $0.638
Upside: n/a